<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - FDA Approves Novel Sickle Cell Disease Treatment
Image Overlay - FDA Approves Novel Sickle Cell Disease Treatment

FDA Approves Novel Sickle Cell Disease Treatment

December 3, 2019

FDA Approves Novel Sickle Cell Disease Treatment

The FDA granted accelerated approval to Oxbryta (voxelotor), a novel inhibitor of deoxygenated sickle hemoglobin polymerization, the central abnormality in patients with sickle cell disease.The Accelerated Approval pathway enables the FDA to approve drugs for serious conditions based on results showing it is likely to provide clinical benefits to patients. Yourway has extensive experience expediting clinical trials to take advantage of fast-tracked approval pathways.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Longwood Healthcare Leaders

October 27-28, 2025
Mandarin Oriental Hotel, Boston

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat
Come chat with us!
Hello! How can I help you?